Skylar Luu

Dr. Skylar Luu

Psychiatry, Rutgers University–Newark, Newark, California, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Current Biology
Verified
Journal Article
Closed access
IBIan D. Blum
Ian D. Blum
MKMehmet F. Keleş
Mehmet F. Keleş
EBEl-Sayed Baz
El-Sayed Baz
EHEmily Han
Emily Han
KPKristen Park
Kristen Park
MWMark N. Wu
Mark N. Wu

11 September 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SLSkylar Luu
Skylar Luu
HPHaley Province
Haley Province
EBElizabeth M. NA Berry-Kravis
Elizabeth M. NA Berry-Kravis
RHRandi Hagerman
Randi Hagerman
DHDavid Hessl
David Hessl
DBDejan B. Budimirovic
Dejan B. Budimirovic
Fragile X syndrome (FXS) is the leading cause of inherited intellectual disability and autism spectrum disorder. Individuals with FXS often present with a wide range of cognitive deficits and problem behaviors. Educational, behavioral and pharmacological interventions are used to manage these and other complex issues affecting individuals with FXS. Despite the success of preclinical models and early-phase drug clinical studies in FXS, large-scale randomized-controlled trials have failed to meet primary endpoints. Currently, no targeted or disease-modifying treatments for FXS have received regulatory approval. Here, we examined the placebo response in FXS clinical trials conducted between 2006 and 2018. Specifically, we performed a meta-analysis of placebo-treated groups in eight double-blind, randomized controlled trials. Placebo groups demonstrated significant improvements on caregiver-rated efficacy endpoints, which were greater in adolescents and adults than in children. Among the latter measures, the Visual Analog Scale scores displayed the greatest improvements, whereas the positive effects on the Vineland-II Adaptive Behavior Composite and the Aberrant Behavior Checklist-Community/fragile X version were statistically significant in both children and adolescents/adults. Although the Clinical Global Impression scale Improvement appears to have exhibited a substantial placebo effect in multiple clinical trials in FXS, limited data availability for meta-analysis, prevented us from drawing conclusions. No placebo-related improvements were observed in performance-rated measures. These findings raise substantial concerns about placebo effects in outcome measures commonly used in the randomized-controlled trials in FXS and suggest several potential improvements in the study design and implementation of such trials. Considering the small number of trials available for this study, larger and more detailed follow up meta-analyses are needed. Meanwhile, efforts to improve the measurement properties of endpoints and rater training in drug trials in FXS should be prioritized.

1 May 2022 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
SMSridhar R. Musuku
Sridhar R. Musuku
MMMohammed Mustafa
Mohammed Mustafa
MPMythili Pulavarthi
Mythili Pulavarthi
IDIsha Doshi
Isha Doshi
YZYikun Zhang
Yikun Zhang
ASAlexander D. Shapeton
Alexander D. Shapeton

5 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
IBIan D. Blum
Ian D. Blum
MKMehmet F. Keleş
Mehmet F. Keleş
EBEl-Sayed Baz
El-Sayed Baz
EHEmily Han
Emily Han
KPKristen Park
Kristen Park
MWMark N. Wu
Mark N. Wu
SUMMARY: Sleep is under homeostatic control, whereby increasing wakefulness generates sleep need and triggers sleep drive. However, the molecular and cellular pathways by which sleep need is encoded are poorly understood. In addition, the mechanisms underlying both how and when sleep need is transformed to sleep drive are unknown. Here, using ex vivo and in vivo imaging, we show in Drosophila that astroglial Ca 2+ signaling increases with sleep need. We demonstrate that this signaling is dependent on a specific L-type Ca 2+ channel and is required for homeostatic sleep rebound. Thermogenetically increasing Ca 2+ in astrocytes induces persistent sleep behavior, and we exploit this phenotype to conduct a genetic screen for genes required for the homeostatic regulation of sleep. From this large-scale screen, we identify TyrRII, a monoaminergic receptor required in astrocytes for sleep homeostasis. TyrRII levels rise following sleep deprivation in a Ca 2+ -dependent manner, promoting further increases in astrocytic Ca 2+ and resulting in a positive-feedback loop. These data suggest that TyrRII acts as a gate to enable the transformation of sleep need to sleep drive at the appropriate time. Moreover, our findings suggest that astrocytes then transmit this sleep need to the R5 sleep drive circuit, by upregulation and release of the interleukin-1 analog Spätzle. These findings define astroglial Ca 2+ signaling mechanisms encoding sleep need and reveal dynamic properties of the sleep homeostatic control system.

19 March 2026 in The Primary Care Companion For CNS Disorders
Verified
Journal Article
Closed access
SLSkylar Luu
Skylar Luu
YKYu Kong
Yu Kong
MSMario Sokolic
Mario Sokolic
ECElizabeth Chern
Elizabeth Chern
ZAZeshawn Ali
Zeshawn Ali
EREric Rutkowski
Eric Rutkowski

20 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JKJessica Klein
Jessica Klein
AMAlexandra Massaro
Alexandra Massaro
BSBradley Susskind
Bradley Susskind
SLSkylar Luu
Skylar Luu
PBPhillip Bempong
Phillip Bempong
DBDejan B. Budimirovic
Dejan B. Budimirovic
Background: Pediatric prescribing of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) is expanding faster than the evidence that supports it, with minimal evidence in the treatment of binge-type eating disorders. Impulsivity is central to the binge eating episodes and compensatory behaviors in binge eating disorder (BED) and bulimia nervosa (BN). This scoping review maps GLP-1 RA use in youth with BED and BN, exploring evidence on psychiatric outcomes and impulsivity as a validated outcome measure. Methods: Using JBI methodology and PRISMA-ScR reporting guidelines, we searched across five databases for both peer reviewed literature and data from non-published poster/oral presentations. Studies were imported to JBI SUMARI and evaluated by two independent reviewers, with any conflicts resolved by a third party. Data was extracted, analyzed, and narratively summarized to identify gaps in existing literature. Results: Of 74 identified abstracts, 11 full texts matched inclusion criteria. Included texts were all published/presented between 2021-2025 with notable variation in study design. Some studies demonstrate promise for the use of GLP-1 RA in reducing binge eating behaviors, while others reveal potential for development of restrictive eating. Of the 11 included studies, none used validated measures for impulsivity as post-treatment outcome measure.Conclusions: Although impulsivity is central to binge-eating type pathology and the mechanism behind GLP-1 RA efficacy, there are no studies investigating the therapeutic effect of these drugs on impulsivity. This scoping review highlights areas of high priority for future study concerning the use of GLP-1 RA in pediatric populations with binge-eating type pathology.